Print Page   |   Sign In   |   Register
Glaucoma Home Monitoring Tools
Tell a Friend About This EventTell a Friend

When: June 18, 2020
6:00 PM to 7:30 PM
Where: Webinar
United States
Contact: Sophie Pumphrey

Online registration is closed.
« Go to Upcoming Event List  


Dr. Richman is a board-certified ophthalmologist and fellowship-trained cataract and glaucoma surgeon. He specializes in the surgical and medical treatment of glaucoma and cataracts. Dr. Richman has patented a novel diagnostic test for the detection and management of glaucoma, named the Spaeth-Richman Contrast Sensitivity Test. He was the first ophthalmologist to implant the iStent trabecular micro bypass in the state of Delaware and has designed a single-step toric marker to aid in the reduction of astigmatism at the time of cataract surgery.

Dr. Jesse Richman


1) Explain how to utilize home monitoring to take better care of your patients

2) Educate the audience about the test design of SPARCS

3) Review the strengths and limitations of SPARCS


The Spaeth / Richman Contrast Sensitivity (SPARCS) test is a website based assessment of central and peripheral vision. It has been used for 10+ years in various clinical trials in patients with glaucoma, cataracts, and macular degeneration. This webinar will explain the test and how you could potentially use it in the care of your patients.


Dr. Johnson is a physician-scientist, glaucoma specialist, and Assistant Professor of ophthalmology at Johns Hopkins’s Wilmer Eye Institute. As a Gates Scholar and NIH-OxCam Scholar, he earned his PhD in neuroscience at the University of Cambridge followed by his MD at Johns Hopkins. He then completed ophthalmology residency and glaucoma fellowship at the Wilmer Eye Institute. His scientific interests include understanding the pathophysiologic mechanisms that lead to retinal ganglion cell (RGC) death in glaucoma and developing novel treatments that are capable of restoring vision in glaucoma and other optic neuropathies. He has broadly investigated aqueous humor dynamics in rodents and humans, mechanisms of pharmacologic intraocular pressure-lowering therapies, and approaches to RGC neuroprotection in models of glaucoma, including through somatic stem cell transplantation. In addition to leading a translational neuroscience laboratory focused on optic nerve regeneration, he is conducting ongoing clinical studies aimed at evaluating the utility of home self-tonometry for the management of glaucoma.




Dr. Thomas Johnson


1) To review data describing the accuracy of self-administered rebound tonometry in comparison to tonometry performed in the clinic.


2) To discuss clinical scenarios in which home IOP monitoring can be particularly useful for managing glaucoma.


3) To describe logistical considerations in obtaining home tonometry measurements in glaucoma patients.



Intraocular pressure (IOP) is the most important modifiable risk factor for the onset and progression of glaucoma, at all baseline IOP levels and at all stages of the disease. The clinical management of glaucoma is based upon in-office IOP measurements using Goldmann applanation tonometry (GAT) as the gold standard for understanding a patient’s IOP-related glaucoma risk, setting IOP targets to guide therapy, and assessing responses to medical and surgical intervention for IOP reduction. Whereas clinicians typically reply on in-office IOP measurements obtained in isolation at intervals of several months to guide management, IOP varies significantly throughout the circadian cycle and on a day-to-day basis. Therefore, in-office tonometry may not fully capture IOP dynamics. Moreover, the relevance of short-term IOP fluctuation in glaucoma is a matter of ongoing debate. Home tonometry using a commercially available FDA approved device can be used to measure IOP outside of the office setting, identify patients with high IOP fluctuation, and track IOP responses to therapy. In light of the COVID-19 pandemic and necessary social distancing, the use of home tonometry for measuring IOP without an in-person clinic visit is attractive. However, data informing the relationship between home tonometry and clinically relevant measures of glaucoma disease progression are lacking. Nonetheless, the role of home tonometry is likely to increase in the near future.



Dr. Alan Robin is a leader in the clinical management and scientific study of glaucoma as well as the global impact of eye care. Dr. Robin holds joint Associate Professorships in Ophthalmology and in International Health at Johns Hopkins University and is a Professor at the University of Michigan. He has been part of the glaucoma fellowship program at the Wilmer Institute, the co-director of the Glaucoma Service at the Greater Baltimore Medical Center and held an active private practice with offices in the Baltimore and southern Pennsylvania areas for 40 years. He is the executive vice president of the American Glaucoma Society.




Dr. Alan Robin


1) Evaluate needs for perimetry and best methods of performing and evaluating perimetry.

2) Evaluate issues with cupola based perimetry.

3) Consider the advantages and disadvantages of tablet based perimetry.






This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of MedChi, The Maryland State Medical Society and the Maryland society of Eye Physicians & Surgeons. MedChi is accredited by the ACCME to provide continuing medical education for physicians

MedChi designates this online educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Community Search
Sign In







Take Advantage of the Third Party Insurance Help Program 

Have a coding question? Use the new MSEPS member benefit!

Copyright © 2014 Maryland Society of Eye Physicians & Surgeons

MSEPS / 1211 Cathedral Street / Baltimore, MD 21201 / 410-244-7320